Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 77Gynecologic 6Gastrointestinal 6Thoracic 5Head & Neck 4Dermatologic 4Breast 4Sarcoma 2Other solid neoplasm 2Lymphoid 2Other hematologic neoplasm 1Myeloid 1Endocrine 1CNS 1

Conditions

Leukemia, Myeloid, Acute 3503Precursor Cell Lymphoblastic Leukemia-Lymphoma 2496Leukemia 2360Leukemia, Lymphocytic, Chronic, B-Cell 1992Myelodysplastic Syndromes 1411Hematologic Neoplasms 1382Lymphoma 1175Lymphoma, Non-Hodgkin 1079Leukemia, Myelogenous, Chronic, BCR-ABL Positive 863Lymphoma, Follicular 761Multiple Myeloma 739Lymphoma, Mantle-Cell 730Lymphoma, Large B-Cell, Diffuse 714Burkitt Lymphoma 691Lymphoma, B-Cell, Marginal Zone 645Hodgkin Disease 636Recurrence 627Leukemia, Myelomonocytic, Chronic 536Neoplasms 516Lymphoma, Large-Cell, Immunoblastic 451Myeloproliferative Disorders 445Leukemia, Myeloid, Chronic-Phase 437Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 414Congenital Abnormalities 411Waldenstrom Macroglobulinemia 360Blast Crisis 353Leukemia, Myeloid, Accelerated Phase 318Lymphoma, T-Cell, Cutaneous 311Primary Myelofibrosis 297Neoplasms, Plasma Cell 276

Interventions

ibrutinib 1JNJ-64619178 1JNJ-64264681 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms, Castration-Resistant × Other hematologic neoplasm × Clear all
NCT06788509 2026-05-08

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

Janssen Research & Development, LLC

Phase 1 Enrolling by invitation
120 enrolled
GenitourinaryLymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡